Acton Pharma gets USFDA nod for an inhaled steroid to treat asthma

By Admin
Acton Pharmaceuticals, Inc Friday said it has secured approval from the U.S. Food and Drug Administration of its supplemental New Drug Application for...

Acton Pharmaceuticals, Inc Friday said it has secured approval from the U.S. Food and Drug Administration of its supplemental New Drug Application for an inhaled steroid to treat asthma, the news reports said.

The FDA approved the application for AEROSPAN, an oral corticosteroid used in treating asthma in adults and kids six and under.

Post getting the approval, the respiratory therapeutics company now plans to launch AEROSPAN into $8.3 billion inhaled steroid market in early 2013, the company said.

Acton Pharma bought AEROSPAN new drug application under the licensing agreement with Forest Laboratories, Inc in 2009.

Acton President Daniel Kreisler said, “Acton anticipates commercial launch of AEROSPAN in the first quarter of 2013 as we build out our sales and marketing infrastructure and evaluate strategic partnerships.” Mr. Kreisler also said, “Our ongoing commercial preparations include building product inventory as well as finalizing the introduction of Aerospan to manage care plans and initiation of pre-launch marketing activities.”

As per the Center for Disease Control, there are more than 24 million Americans with asthma and the disease is the cause for nearly 2 million emergency visits each and $11.5 billion in healthcare costs.

Acton Pharmaceuticals, Inc is a respiratory specialty pharmaceutical company. It focuses on acquisition, development, and commercialization of products to treat allergic, pulmonary, and other respiratory related diseases.

Share
Share

Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI

AI & ML

Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI